Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ultrasound-Guided diuretic dosing may improve heart failure hospital outcomes

NCT ID NCT07469722

Disease control Sponsor: Hospital de Clinicas de Porto Alegre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using a special ultrasound score (DUCS) to guide diuretic dosing can improve outcomes for people hospitalized with acute heart failure. About 128 adults with heart failure and fluid buildup will be randomly assigned to either standard care or ultrasound-guided treatment. The goal is to see if the ultrasound approach reduces deaths, shortens hospital stays, and clears fluid more effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 128 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men or women aged 18 years or older. * Diagnosis of acute decompensated heart failure (ADHF) with left ventricular ejection fraction \<50%, presenting with symptoms (dyspnea, orthopnea, fatigue) and/or signs (pulmonary crackles, peripheral edema, jugular venous distension, hepatomegaly, hepatojugular reflux) of decompensated heart failure. * Brain natriuretic peptide (BNP) ≥ 300 pg/mL. * Signs of systemic and/or pulmonary congestion on POCUS, defined as DUCS ≥ 3 points. * Time from hospital admission ≤ 48 hours. * Signed informed consent. Exclusion Criteria: * Patients under evaluation for heart transplantation or with prior heart transplantation. * Acute coronary syndrome as the primary cause of hospitalization. * Evidence of uncontrolled infection. * Cardiac surgery or percutaneous coronary or structural cardiac intervention within the previous 30 days. * Signs of hypoperfusion, defined as any of the following: mean arterial pressure \< 60 mmHg, capillary refill time \> 4 seconds, arterial lactate \> 2 mmol/L or venous lactate \> 2.5 mmol/L. * Acute pulmonary embolism (segmental or more proximal) as the primary cause of hospitalization. * Acute stroke. * Chronic kidney disease stage 5 (estimated glomerular filtration rate \< 15 ml/min/m²) or requirement for renal replacement therapy. * Liver cirrhosis with portal hypertension. * Known pulmonary disease with extensive parenchymal involvement, including interstitial lung disease, pulmonary metastases, prior pneumonectomy, lobectomy, or pleurodesis. * Severe hypokalemia (serum potassium \< 2.5 mmol/L). * Pregnancy or breastfeeding. * Refusal to participate in the clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute heart failure (AHF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute heart failure (AHF) Congestive heart failure acute Diuretic effect Lung ultrasonography score Point of care ultrasound (pocus) Ultrasonography, doppler

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, 90410-000, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.